eli lilly's tirzepatide is the leader in weight loss sector Zepbound Tops Novo Nordisk's Wegovy Weight-Loss Trial Eli Lilly's weight loss drug

Research now shows that the body may respond to a calorie-deficit diet by increasing hunger and reducing feelings of fullness, making weight loss more difficult

Dual Agonist Therapies Fundamentally, tirzepatide and semaglutide work by mimicking natural hormones that regulate appetite and blood sugar

It mimics a hormone in your body that helps regulate blood sugar, slows digestion, and decreases appetite

Wegovy is the brand approved for chronic weight management, while Ozempic is approved for type 2 diabetes

2), S279S284

By synthesizing trial outcomes, labeling guidance, and clinical practice considerations, this comparison supports providers in determining which medication aligns best with an individual patients metabolic profile, treatment goals, and risk factors